SCHEMBL1286734

SCHEMBL1286734

CCOC(=O)C(Br)CC(Br)C(=O)OCC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.46
TRPA1 O75762 1/20 0.44
LMNA P02545 1/20 0.43
HSD17B10 Q99714 1/20 0.43
ALOX15 P16050 1/20 0.42
MGAM O43451 1/20 0.42
GAA P10253 1/20 0.42
SI P14410 1/20 0.42
MGAM2 Q2M2H8 1/20 0.42
SOAT1 P35610 1/20 0.42
ZDHHC7 Q9NXF8 1/20 0.38
PIN1 Q13526 1/20 0.35
HCAR2 Q8TDS4 1/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
KMT2A Q03164 1/20 0.34
CAD P27708 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14016338 1.00 ALDH1A1 (0.46) ALDH1A1TRPA1LMNAHSD17B10ALOX15
SCHEMBL18397555 0.91 ALDH1A1 (0.41) ALDH1A1TRPA1LMNAHSD17B10ALOX15
SCHEMBL1370661 0.88 ALDH1A1 (0.40) ALDH1A1TRPA1LMNAHSD17B10ALOX15
SCHEMBL30520135 0.88 ALDH1A1 (0.40) ALDH1A1TRPA1LMNAHSD17B10ALOX15
SCHEMBL20328792 0.86 ALDH1A1 (0.39) ALDH1A1TRPA1LMNAHSD17B10ALOX15
SCHEMBL12539120 0.86 CYP3A4 (0.45) ALDH1A1TRPA1LMNAHSD17B10ALOX15
SCHEMBL20332953 0.86 CYP3A4 (0.45) ALDH1A1TRPA1LMNAHSD17B10ALOX15
SCHEMBL25626564 0.84 CPB2 (0.40) ALDH1A1TRPA1LMNAHSD17B10ALOX15
SCHEMBL189345 0.84
SCHEMBL36999 0.84 ZDHHC7 (0.47) ALDH1A1TRPA1LMNAHSD17B10ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113603683-B Substituted phenyl oxazolidinones for antimicrobial treatment 结核病药物开发全球联盟公司 2024-06-14 CN disclosed
US-11964949-B2 Substituted phenyloxazolidinones for antimicrobial therapy THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) 2024-04-23 US disclosed
US-11649244-B2 Method for synthesizing diaza-bridged compound and a diaza-bridged compound LinkChem Co., Ltd., Shanghai (CN) 2023-05-16 US disclosed
US-11649244-B2 Method for synthesizing diaza-bridged compound and a diaza-bridged compound LinkChem Co., Ltd., Shanghai (CN) 2023-05-16 US disclosed
US-11649244-B2 Method for synthesizing diaza-bridged compound and a diaza-bridged compound LinkChem Co., Ltd., Shanghai (CN) 2023-05-16 US disclosed
CN-113999152-B Synthesis method of cis-1-benzyl-2, 4-dialkoxycarbonyl azetidine 上海凌富药物研究有限公司 2023-05-09 CN disclosed
CN-113999239-B Method for synthesizing diaza-bridge compound 上海凌富药物研究有限公司 2022-11-11 CN disclosed
US-20220119397-A1 Method for Synthesizing Diaza-Bridged Compound and a Diaza-Bridged Compound LINKCHEM TECHNOLOGY CO., LTD. (CN) 2022-04-21 US disclosed
CN-113999152-A Synthesis method of cis-1-benzyl-2, 4-dialkoxy carbonyl azetidine 上海凌富药物研究有限公司 2022-02-01 CN disclosed
CN-113999239-A Method for synthesizing diaza-bridge compound 上海凌富药物研究有限公司 2022-02-01 CN disclosed
EP-1714993-A1 THERMOPLASTIC ELASTOMER COMPOSITION AND MOLDED ARTICLE KANEKA CORPORATION (JP) 2006-10-25 EP disclosed
EP-1714992-A1 THERMOPLASTIC ELASTOMER COMPOSITION AND MOLDED ARTICLE Kaneka Medix Corporation (JP) 2006-10-25 EP disclosed
EP-1669406-A1 THERMOPLASTIC ELASTOMER COMPOSITION KANEKA CORPORATION (JP) 2006-06-14 EP disclosed
US-20050272865-A1 Block copolymer KANEKA CORPORATION 2005-12-08 US disclosed
US-20050234199-A1 Acrylic block copolymer and thermoplastic resin composition KANEKA CORPORATION (JP) 2005-10-20 US disclosed
EP-1541595-A1 ACRYLIC BLOCK COPOLYMER AND THERMOPLASTIC RESIN COMPOSITION KANEKA CORPORATION (JP) 2005-06-15 EP disclosed
US-20050085592-A1 Block copolymer KANEKA CORPORATION (JP) 2005-04-21 US disclosed
EP-1475397-A1 BLOCK COPOLYMER KANEKA CORPORATION (JP) 2004-11-10 EP disclosed
US-20040147674-A1 Thermoplastic resin composition KANEKA CORPORATION (JP) 2004-07-29 US disclosed
EP-1398353-A1 THERMOPLASTIC RESIN COMPOSITION Kaneka Corporation (JP) 2004-03-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11964949-B2 Substituted phenyloxazolidinones for antimicrobial therapy THPO, TBCD, OXA1L ALDH1A1 1310/4885TRPA1 2957/4885LMNA 3725/4885
US-20220119397-A1 Method for Synthesizing Diaza-Bridged Compound and a Diaza-Bridged Compound DGAT2, NOS2, ABL1 ALDH1A1 1040/4885TRPA1 76/4885LMNA 3062/4885
US-11649244-B2 Method for synthesizing diaza-bridged compound and a diaza-bridged compound DGAT2, NOS2, ABL1 ALDH1A1 1040/4885TRPA1 76/4885LMNA 3062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.